<DOC>
	<DOCNO>NCT02771093</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , parallel-group comparative , exploratory study evaluate effect trelagliptin administer dose 100 mg weekly alogliptin administer dose 25 mg daily 4 week glycemic variation patient type 2 diabetes mellitus use continuous glucose monitoring ( CGM ) .</brief_summary>
	<brief_title>An Exploratory Study Evaluate Effects Trelagliptin Alogliptin CGM Glucose Variability One Week With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The purpose study evaluate effect trelagliptin administer orally dose 100 mg weekly alogliptin administer orally dose 25 mg daily 4 week glycemic variation exploratory manner preliminary examine influence once-weekly administration blood glucose fluctuation due difference daily administration participant type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Participants , opinion principal investigator investigator , capable understanding content clinical research comply research protocol requirement . 2 . Participants able sign date inform consent form information sheet prior start study procedure 3 . Participants diagnose type 2 diabetes mellitus 4 . Participants HbA1c ( NGSP value ) value ≥ 6.5 % &lt; 8.5 % start observation period ( Day 2 ) 5 . Participants experience ≤ ±1.0 % change HbA1c ( NGSP value ) start observation period ( Day 2 ) compare HbA1c value obtain precede 4 week 6 . Participants receive stable dietetic therapy exercise therapy ( perform ) ≥ 4 week start observation period 7 . Participants , opinion principal investigator investigator , change ( include discontinuation interruption ) HMGCoA reductase inhibitor add new HMGCoA reductase inhibitor treatment period . 8 . Men woman age 20 year old time inform consent . 1 . Participants receive antidiabetic medication within 4 week prior start observation period 2 . Participants change ( include discontinuation interruption ) HMGCoA reductase inhibitor receive new HMGCoA reductase inhibitor ≤ 4 week start observation period . 3 . Participants clinically evident hepatic dysfunction ( e.g. , AST ALT ≥ 2.5fold upper limit normal start observation period [ Day 2 ] ) 4 . Participants moderate renal dysfunction , severe renal dysfunction renal failure ( e.g. , creatinine clearance &lt; 50 mL/min serum creatinine &gt; 1.4 mg/dL men &gt; 1.2 mg/dL woman [ equivalent creatinine clearance person age 60 year body weight 65 kg ] start observation period [ Day 2 ] ) 5 . Participants severe heart disease , cerebrovascular disorder , severe pancreatic , hematologic diseases 6 . Participants history gastric small intestinal resection 7 . Participants proliferative diabetic retinopathy 8 . Participants warrant insulin therapy glycemic control ( e.g. , participant severe ketosis , diabetic coma precoma , type 1 diabetes mellitus , severe infection , perioperative participant , serious trauma ) 9 . Participants history hypersensitivity allergy DPP4 inhibitor 10 . Participants experience allergic reaction metal CGM start observation period ( Day 2 ) 11 . Participants malignant tumor 12 . Habitual drinker whose average daily alcohol consumption &gt; 100 mL 13 . Participants contraindication study drug taking contraindicate concomitant drug list package insert 14 . Participants anticipated require prohibit concomitant medication study period 15 . Participants day night lifestyle reversal 16 . Participants participate clinical study time inform consent study 17 . Pregnant woman , nurse mother , woman possible pregnant , woman plan become pregnant 18 . Other participant consider inappropriate participation study opinion principal investigator investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 , Diabetes , Diabetes Mellitus</keyword>
</DOC>